We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Identify Genes Linked to the Development of Monogenic Diabetes

By LabMedica International staff writers
Posted on 02 Mar 2020
Print article
Image: Photomicrograph of a pancreatic islet, showing insulin-producing beta cells (Photo courtesy of Wikimedia Commons)
Image: Photomicrograph of a pancreatic islet, showing insulin-producing beta cells (Photo courtesy of Wikimedia Commons)
By studying a well controlled group of young Lithuanian diabetes patients, researchers were able to identify genes linked to the development of the rare monogenic form of diabetes.

Monogenic diabetes, which results from a mutation in one of the genes involved in the regulation of blood sugar levels, represents approximately one to 4% of all cases of the disease. Monogenic diabetes is frequently confused with type I or type II diabetes, and more than 90% of monogenic cases are misdiagnosed.

To correct this situation, investigators at the Université de Genève (Switzerland) and the Lithuanian University of Health Sciences (Vilnius) took advantage of the fact that Lithuania has a register of all diabetic children, which also includes most of the young adults. For the current study, the investigators assessed 1209 pediatric and young adult diabetic patients for diabetes-related autoimmune antibodies. They then screened all antibody-negative patients using targeted high-throughput sequencing of more than 300 potential candidate genes.

Results revealed that in the group of 153 patients lacking autoimmune antibodies, 40.7% had monogenic diabetes, with the highest percentage (100%) in infants (diagnosis at ages 0–12 months), followed by those diagnosed at ages from one to 18 years (40.3%) and at 18 to 25 years (22.2%).

The overall prevalence of monogenic diabetes in diabetic youth in Lithuania was 3.5% (1.9% for glucokinase diabetes, 0.7% for hepatocyte nuclear factor 1 homeobox A, 0.2% for hepatocyte nuclear factor 4 alpha and ATP binding cassette subfamily C member 8, 0.3% for potassium inwardly rectifying channel subfamily J member 11, and 0.1% for insulin). Likely pathogenic variants were also detected in 11 additional genes.

"Hyperglycemia should therefore be considered as a symptom of various diseases, rather than a disease in itself, and different forms of diabetes should be better screened," said senior author Dr. Valérie Schwitzgebel, professor of pediatrics, gynaecology, and obstetrics at Université de Genève. "The earlier the actual cause is identified, the sooner appropriate treatments can be initiated, minimizing the risk for long term complications."

The monogenic diabetes paper was published in the February 21, 2020, online edition of the journal Diabetes.

Related Links:
Université de Genève
Lithuanian University of Health Sciences


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.